Aug
4
The class-action drug injury lawsuit will involve multiple plaintiffs who will file the action in order to achieve the necessary financial compensation. Such class actions are extremely beneficial for all the patients who were affected by the use of Trasylol during their bypass surgeries. For instance, the cost of an individual lawsuit is likely to overwhelm the plaintiff while the class-action lawsuit makes pursuing a claim more economical for individuals. The plaintiffs will not be overwhelmed by the costs of the process and they are more likely to get fair and reasonable compensation. By using the class-action Trasylol kidney failure lawsuit, every plaintiff can make their individual where in other situations they might not be able to bring a claim.
Bayer is preparing to defend Trasylol lawsuits from around the United States that could number in the thousands as the public becomes more aware of the devastating side effects of this heart drug medication. Trasylol claims brought on behalf of individuals and families of heart surgery patients throughout the United States have been filed against the drug giant Bayer. Currently Trasylol lawsuits are being filed by individuals and families throughout the United States. No Trasylol class actions have been filed, however given the number of potential Trasylol victims, attorneys and courts will likely look to multidistrict litigation and class actions to more efficiently handle the growing number of cases.
Bayer’s growing Trasylol problems follow increasing reports of the drug’s side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved by the Federal Drug Administration. Aprotinin is manufactured by Bayer under the brand name Trasylol. Until it was recently withdrawn from the market, Trasylol sales continued to increase even though studies indicated serious Trasylol kidney damage side effects.
The FDA began a closer examination of the safety of Trasylol in January 2006 after the publication of studies linking the drug to dangerous side effects including heart attacks, kidney problems and strokes. In light of the preliminary BART study information, the FDA anticipates re-evaluating the risks and benefits of Trasylol. The FDA worked with Bayer to carefully phase Trasylol out of the marketplace in an attempt to prevent shortages of other drugs used prevent excessive bleeding during cardiac surgery. This phase-out however, led to the continued use of Trasylol during bypass surgeries until May 2008.
A recent study based on observations at 69 leading cardiac centers throughout the world was published regarding Bayer Pharmaceutical’s heart surgery drug Trasylol. Kidney failure, heart failure, and stroke are side effects associated with Trasylol heart surgery patients according to the study published by Mangano et al. in January 2006 in the New England Journal of Medicine (NEJM).
On November 5, 2007 the Food and Drug Administration (FDA) announced that Bayer Pharmaceuticals Corp. had withdrawn Trasylol from the marketplace. Recall of this controversial drug at the request of the FDA was based on initial data from a Canadian study that compared heart surgery drugs used to help reduce bleeding during bypass surgery.
Each year approximately one million patients undergo surgery following a heart attack. Prior the Trasylol recall, the majority of patients who were at increased risk of bleeding during surgery have the option of one of three antifibrinolytic drugs to limit blood loss: Trasylol (Aprotinin), Amicar (aminocaproic acid), or Cyklokapron (tranexamic acid). These drugs work by inactivating an enzyme called plasmin so it stops from breaking down blood clots which helps prevent bleeding.
By: Jhoana Cooper
About the Author:
Bayer is preparing to defend Trasylol lawsuits from around the United States that could number in the thousands as the public becomes more aware of the devastating side effects of this heart drug medication. Trasylol claims brought on behalf of individuals and families of heart surgery patients throughout the United States have been filed against the drug giant Bayer. Currently Trasylol lawsuits are being filed by individuals and families throughout the United States. No Trasylol class actions have been filed, however given the number of potential Trasylol victims, attorneys and courts will likely look to multidistrict litigation and class actions to more efficiently handle the growing number of cases.
Bayer’s growing Trasylol problems follow increasing reports of the drug’s side effects. Trasylol has recently been linked to a higher risk of kidney failure, heart attack, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved by the Federal Drug Administration. Aprotinin is manufactured by Bayer under the brand name Trasylol. Until it was recently withdrawn from the market, Trasylol sales continued to increase even though studies indicated serious Trasylol kidney damage side effects.
The FDA began a closer examination of the safety of Trasylol in January 2006 after the publication of studies linking the drug to dangerous side effects including heart attacks, kidney problems and strokes. In light of the preliminary BART study information, the FDA anticipates re-evaluating the risks and benefits of Trasylol. The FDA worked with Bayer to carefully phase Trasylol out of the marketplace in an attempt to prevent shortages of other drugs used prevent excessive bleeding during cardiac surgery. This phase-out however, led to the continued use of Trasylol during bypass surgeries until May 2008.
A recent study based on observations at 69 leading cardiac centers throughout the world was published regarding Bayer Pharmaceutical’s heart surgery drug Trasylol. Kidney failure, heart failure, and stroke are side effects associated with Trasylol heart surgery patients according to the study published by Mangano et al. in January 2006 in the New England Journal of Medicine (NEJM).
On November 5, 2007 the Food and Drug Administration (FDA) announced that Bayer Pharmaceuticals Corp. had withdrawn Trasylol from the marketplace. Recall of this controversial drug at the request of the FDA was based on initial data from a Canadian study that compared heart surgery drugs used to help reduce bleeding during bypass surgery.
Each year approximately one million patients undergo surgery following a heart attack. Prior the Trasylol recall, the majority of patients who were at increased risk of bleeding during surgery have the option of one of three antifibrinolytic drugs to limit blood loss: Trasylol (Aprotinin), Amicar (aminocaproic acid), or Cyklokapron (tranexamic acid). These drugs work by inactivating an enzyme called plasmin so it stops from breaking down blood clots which helps prevent bleeding.
By: Jhoana Cooper
About the Author:
Trasylol kidney failure lawsuit can provide you with the ability to achieve the fairest compensation. Therefore, you should investigate the class-action drug injury lawsuit and its successful results as a compensation for your Trasyol claim.
Trasylol kidney failure lawsuit, drug injury lawsuit